AN INNOVATIVE APPROACH TO CHOOSING A HORMONAL CONTRACEPTIVE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To carry out a systematic analysis of the data available in modern literature on the choice of hormonal contraception, by taking into account the safety and individual needs of women. Material and methods. The review included the data of foreign and Russian papers published in the past 15years and found in Pubmed on this topic. Results. The paper presents an update on the reasoned choice of hormonal contraception for reproductive-aged and premenopausal women. Conclusion. When choosing a contraceptive, one must take into account not only its safety and efficacy, but also individual needs and additional benefits.

Full Text

Restricted Access

About the authors

Mariana A. Gevorkyan

Honored Doctor of Russia, M.D., Professor, Department of Obstetrics and Gynecology, Medical Faculty, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia 127473, Russia, Moscow, Delegatskaya str. 20, bld. 1

Igor B. Manukhin

Honored Doctor of Russia, M.D., Professor, Head of the Department of Obstetrics and Gynecology, Medical Faculty, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia. 127473, Russia, Moscow, Delegatskaya str. 20, bld. 1

Ekaterina I. Manukhina

MD, Professor, Department of Obstetrics and Gynecology, Medical Faculty, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia 127473, Russia, Moscow, Delegatskaya str. 20, bld. 1

Alexander L. Tikhomirov

MD, Professor, Department of Obstetrics and Gynecology, Medical Faculty, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia 127473, Russia, Moscow, Delegatskaya str. 20, bld. 1

Nara R. Karakashyan

graduate student, senior laboratory assistant of the Department of Obstetrics and Gynecology, Medical Faculty, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia 127473, Russia, Moscow, Delegatskaya str. 20, bld. 1

References

  1. Medical eligibility criteria for contraceptive use. 5th ed. WHO; 2015.
  2. Подзолкова Н.М., Ерофеева Л.В., Сафина Э.М., Сумятина Л.В. Мифы о контрацепции в современной России. Фарматека. 2014; 12: 8-11. [Podzolkova N.M., Erofeeva L.V., Safina E.M., Sumyatina L.V. Myths about contraception in modern Russia. Farmateka. 2014; 12: 8-11. (in Russian)]
  3. Прилепская В.Н., ред. Руководство по контрацепции. М.: МЕДпресс-информ; 2006. 400с. [Prilepskaya V.N., ed. Contraceptive Guide. Moscow: MEDpress-inform; 2006. 400p. (in Russian)]
  4. Данченко О.В., Шимановский Н.Л. Эффективность и безопасность длительного применения препарата Диане-35 для лечения симптомов андрогенизации. Русский медицинский журнал. 2000; 8(11): 449-53. [Danchenko O.V., Shimanovskiy N.L. Efficacy and safety of prolonged use of the drug Diane-35 for the treatment of symptoms androgenization. Russkiy meditsinskiy zhurnal. 2000; 8(11): 449-53. (in Russian)]
  5. Манухин И.Б., Тумилович Л.Г., Геворкян М.А. Клинические лекции по гинекологической эндокринологии. М.: ГЭОТАР-Медиа; 2013. [Manuhin I.B., Tumilovich L.G., Gevorkyan M.A. Clinical lectures on gynecological endocrinology. Moscow: GEOTAR-Media; 2013. (in Russian)]
  6. Fenton C., Wellington K., Moen M.D., Robinson D.M. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris. Drugs. 2007; 67(12): 1749-65.
  7. Радзинский В.Е., Полина М.Л. Гестаген IV поколения дроспиренон: новое явление в современной гинекологии? Клиническая лекция. М.: Редакция журнала StatusPraesens; 2011. 20с. [Radzinskiy V.E., Polina M.L. Progestogen drospirenone generation IV: a new phenomenon in modern gynecology? Clinical lecture. Moscow: Redaktsiya zhurnala StatusPraesens; 2011. 20p. (in Russian)]
  8. Lopez L.M., Kaptein A.A., Helmerhorst F.M. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst. Rev. 2012; (2): CD006586.
  9. Радзинский В.Е., Пустотина О.А. Планирование семьи в XXI веке. М.: ГЭОТАР-Медиа; 2015. 256с. [Radzinskiy V.E., Pustotina O.A. Family planning in the XXI century. Moscow: GEOTAR-Media; 2015. 256p. (in Russian)]
  10. Volumetric concept test. Ipsos; 2014.
  11. Market research of COCs market potential. GFK; 2012.
  12. Royal College of Obstetricians & Gynaecologists. Faculty of sexual & reproductive healthcare. Clinical guidance Progestogen-only pills. 2009. 19p.
  13. Bjarnadöttir R.I., Gottfredsdöttir H., Sigurdardöttir K., Geirsson R.T., Dieben T.O. Comparative study of the effects of a progestogen-only pill containing desogestrel and an intrauterine contraceptive device in lactating women. BJOG. 2001; 108(11): 1174-80.
  14. Корсунская И.М., Доброхотова Ю.Э., Рагимова З.Э., Кузьмина Т.С., Потекаев Н.Н., Баджелан Б. Терапия акне у женщин на фоне гиперандрогении. Consilium medicum. Дерматология. 2008; 1: 6-9. [Korsunskaya I.M., Dobrohotova Yu.E., Ragimova Z.E., Kuzmina T.S., Potekaev N.N., Badzhelan B. Treatment of acne in women on the background of hyperan-drogenism. Consilium medicum. Dermatologiya. 2008; 1: 6-9. (in Russian)]
  15. Прилепская В.Н. Гормональная контрацепция. Клинические лекции. М.: ГЭОТАР-Медиа; 2014. 256с. [Prilepskaya V.N. Hormonal contraception. Clinical lectures. Moscow: GEOTAR-Media; 2014. 256p. (in Russian)]
  16. Aydinlik S., Kaufman J., Lachnit-Fixson U., Lehnert J. Long-term therapy of signs of androgenisation with a low-dosed antiandrogen-oestrogen combination. Clin. Trials J. 1990; 27(6): 392-402.
  17. Кулаков В.И., Прилепская В.Н., Радзинский В.Е., ред. Руководство по амбулаторно-поликлинической помощи в акушерстве и гинекологии (Гормональная контрацепция). М.: ГЭОТАР-Медиа; 2006: 687-704. [Kulakov V.I., Prilepskaya V.N., Radzinskiy V.E., ed. Guidelines for outpatient care in obstetrics and gynecology (hormonal contraception). Moscow: GEOTAR-Media; 2006: 687-704. (in Russian)]
  18. Caprio M., Antelmi A., Chetrite G., Muscat A., Mammi C., Marzolla V. et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist dro-spirenone: potential implications for the treatment of metabolic syndrome. Endocrinology. 2011; 152(1): 113-25.
  19. Пасман Н.М. Дроспиренон - гестаген XXI века с антиминералокортикоидной активностью. Гинекология. 2004; 6(2): 92-6. [Pasman N.M. Drospirenone - progestogen twenty-first century with the anti-mineralocorticoid activity. Ginekologiya. 2004; 6(2): 92-6. (in Russian)]
  20. Кузнецова И.В. Приемлемость и переносимость комбинированного контрацептива, содержащего этинилэстрадиол и дроспиренон. Российский вестник акушера-гинеколога. 2005; 5(5): 32-5. [Kuznetsova I.V. The acceptability and tolerability of a combined contraceptive containing drospirenone and ethinylestradiol. Rossiyskiy vestnik akushera-ginekologa. 2005; 5(5): 32-5. (in Russian)]
  21. Геворкян М., Манухин И.Б., Кузнецова Е.М. Опыт применения дроспиренон-содержащего гормонального контрацептива. Русский медицинский журнал. 2011; 19(2): 24-33. [Gevorkyan M., Manuhin I.B., Kuznetsova E.M. Experience in the use of drospirenone - containing hormonal contraceptive. Russkiy meditsinskiy zhurnal. 2011; 19(2): 24-33. (in Russian)]

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies